Clopidogrel to Treat Patients With Non–ST-Segment Elevation Acute Coronary Syndromes After Hospital Discharge

Authors:
  • MRMatthew T. Roe
    Matthew T. Roe
  • JMJyotsna Mulgund
    Jyotsna Mulgund
  • LNL. Kristin Newby
    L. Kristin Newby
  • SSSidney C. Smith
    Sidney C. Smith
  • CPCharles V. Pollack
    Charles V. Pollack
  • DFDan J. Fintel
    Dan J. Fintel
  • CCChristopher P. Cannon
    Christopher P. Cannon
  • DBDeepak L. Bhatt
    Deepak L. Bhatt
  • WGW. Brian Gibler
    W. Brian Gibler
  • EOE. Magnus Ohman
    E. Magnus Ohman
  • EPEric D. Peterson
    Eric D. Peterson

Abstract
Non–ST-segment elevation acute coronary syndromes (NSTE ACS) result in approximately 1.4 million admissions to US hospitals each year.1 In the past decade, antiplatelet and antithrombotic drugs for the treatment of NSTE ACS that have shown benefits in randomized clinical trials have been incorporated into clinical practice guidelines.2-5

This publication has 1 reference indexed in Scilit: